Stakeholders Prefer TGA’s Modified Approach to Naming Biologics Over FDA’s Suffixes

Drug Industry Daily
An Australian Therapeutic Goods Administration proposal to expand the information offered in its current naming system for biologics drew support from most respondents, with Mylan warning an alternate proposal to adopt suffixes may offer little benefit for pharmacovigilance.

To View This Article:


Subscribe To Drug Industry Daily